Encorafenib

Braftovi®

Inhibition of the V600-mutated BRAF kinase.

12/2019

In combination with binimetinib for unresectable or metastatic melanoma with a BRAF V600 mutation.

Differential blood count, blood chemistry panel, glucose, high-sensitivity troponin T, troponin I, NT-proBNP, S-100, blood pressure, ECG (QT interval < 500 ms), echocardiography (LVEF > 50%).

Dermatological examination.

Ophthalmological examination (if ophthalmological symptoms occur).

Once a month: Differential blood count, blood chemistry panel, glucose, S-100, blood pressure.

Once a month through month 3, then once a quarter: ECG (QT interval).

Dermatological examination: once per quarter

After 4 weeks, then once per quarter: echocardiography, high-sensitivity troponin T, troponin I, NT-proBNP.

Ophthalmological examination if changes in visual acuity occur.

Treatment should be continued until the patient no longer derives benefit from it or unacceptable toxicity occurs.

450 mg once daily orally in combination with binimetinib.

Use caution when taking this medication concurrently with strong CYP2C8 and CYP3A4 inhibitors (e.g., grapefruit, itraconazole) or inducers (e.g., St. John's wort, rifampicin, phenytoin, carbamazepine)

See medical literature, guidelines, and study results.